{"title":"在复发/难治性多发性骨髓瘤中对Elotuzumab联合Pomalidomide和地塞米松的纠正：多中心的延长随访，321例对照临床试验之外的回顾性现实世界经验","authors":"","doi":"10.1002/hon.70039","DOIUrl":null,"url":null,"abstract":"<p>Martino EA, Palmieri S, Galli M, et al. Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trials. <i>Hematol Oncol</i>. 2024;42(4):e3290. https://doi.org/10.1002/hon.3290</p><p>In the article, affiliation 42 for author Barbara Gamberi is not correct. The correct affiliation for Dr. Barbara Gamberi is “Hematology Unit, Azienda Unità Sanitaria Locale – IRCCS of Reggio Emilia, Reggio Emilia, Italy”.</p><p>We apologize for this error.</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 1","pages":""},"PeriodicalIF":3.9000,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.70039","citationCount":"0","resultStr":"{\"title\":\"Correction to Elotuzumab Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Extended Follow-Up of a Multicenter, Retrospective Real-World Experience With 321 Cases Outside of Controlled Clinical Trials\",\"authors\":\"\",\"doi\":\"10.1002/hon.70039\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Martino EA, Palmieri S, Galli M, et al. Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trials. <i>Hematol Oncol</i>. 2024;42(4):e3290. https://doi.org/10.1002/hon.3290</p><p>In the article, affiliation 42 for author Barbara Gamberi is not correct. The correct affiliation for Dr. Barbara Gamberi is “Hematology Unit, Azienda Unità Sanitaria Locale – IRCCS of Reggio Emilia, Reggio Emilia, Italy”.</p><p>We apologize for this error.</p>\",\"PeriodicalId\":12882,\"journal\":{\"name\":\"Hematological Oncology\",\"volume\":\"43 1\",\"pages\":\"\"},\"PeriodicalIF\":3.9000,\"publicationDate\":\"2025-01-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.70039\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hematological Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/hon.70039\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematological Oncology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/hon.70039","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
Martino EA, Palmieri S, Galli M，等。Elotuzumab联合泊马度胺和地塞米松治疗复发/难治性多发性骨髓瘤：321例对照临床试验外的多中心、回顾性现实世界经验的延长随访。中华血液学杂志；2009;42(4):391 - 391。https://doi.org/10.1002/hon.3290In这篇文章，作者Barbara Gamberi的从属关系是不正确的。Barbara Gamberi博士的正确所属单位是“意大利雷焦艾米利亚，雷焦艾米利亚，Azienda unitune Sanitaria Locale - IRCCS of Reggio Emilia”。我们为这个错误道歉。
Correction to Elotuzumab Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Extended Follow-Up of a Multicenter, Retrospective Real-World Experience With 321 Cases Outside of Controlled Clinical Trials
Martino EA, Palmieri S, Galli M, et al. Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trials. Hematol Oncol. 2024;42(4):e3290. https://doi.org/10.1002/hon.3290
In the article, affiliation 42 for author Barbara Gamberi is not correct. The correct affiliation for Dr. Barbara Gamberi is “Hematology Unit, Azienda Unità Sanitaria Locale – IRCCS of Reggio Emilia, Reggio Emilia, Italy”.
期刊介绍：
Hematological Oncology considers for publication articles dealing with experimental and clinical aspects of neoplastic diseases of the hemopoietic and lymphoid systems and relevant related matters. Translational studies applying basic science to clinical issues are particularly welcomed. Manuscripts dealing with the following areas are encouraged:
-Clinical practice and management of hematological neoplasia, including: acute and chronic leukemias, malignant lymphomas, myeloproliferative disorders
-Diagnostic investigations, including imaging and laboratory assays
-Epidemiology, pathology and pathobiology of hematological neoplasia of hematological diseases
-Therapeutic issues including Phase 1, 2 or 3 trials as well as allogeneic and autologous stem cell transplantation studies
-Aspects of the cell biology, molecular biology, molecular genetics and cytogenetics of normal or diseased hematopoeisis and lymphopoiesis, including stem cells and cytokines and other regulatory systems.
Concise, topical review material is welcomed, especially if it makes new concepts and ideas accessible to a wider community. Proposals for review material may be discussed with the Editor-in-Chief. Collections of case material and case reports will be considered only if they have broader scientific or clinical relevance.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
